blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability

2022.02.11

More...
blank News flashes

Italy joins the Federated Register

Click here for more information on the Federated Register.

2025-06-12

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register User Manual
European Patent Register – pocket guide
FAQ - European Patent Register
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP2041068

EP2041068 - POSITIVELY CHARGED WATER-SOLUBLE PRODRUGS OF IBUPROFEN WITH VERY FAST SKIN PENETRATION RATE [Right-click to bookmark this link]
StatusNo opposition filed within time limit
Status updated on  01.12.2017
Database last updated on 09.04.2026
FormerThe patent has been granted
Status updated on  23.12.2016
FormerGrant of patent is intended
Status updated on  18.11.2016
Most recent event   Tooltip11.10.2019Lapse of the patent in a contracting state
New state(s): CY		published on 13.11.2019  [2019/46]
Applicant(s)For all designated states
Techfields Biochem Co. Ltd
Techfields Biochem 2399 Jinqiu Road 129
Shanghai N/A 200444 / CN
For all designated states
Yu, Chongxi
3121 University Blvd West
E-7
Kensington, MD 20895 / US
[2017/04]
Former [2009/14]For all designated states
Techfields Biochem Co. Ltd
Techfields Biochem 2399 Jinqiu Road 129
Shanghai N/A 200444 / CN
For all designated states
Yu, Chongxi
Techfields Biochem 12952 Stockton Avenue
Plainfield, Illinois 60585 / US
Inventor(s)01 / YU, Chongxi
Techfields Biochem
12952 Stockton Ave.
Plainfield, IL 60585 / US
02 / XU, Lina
Techfields Biochem Co. LTD.
2399 Jinqiu Road, 129
Shanghai N/A 200444 / CN
 [2017/04]
Former [2009/14]01 / YU, Chongxi
Techfields Biochem 12952 Stockton Ave.
Plainfield, IL 60585 / US
02 / XU, Lina
Techfields Biochem Co. LTD. 2399 Jinqiu Road, 129
Shanghai N/A 200444 / CN
Representative(s)Finnegan Europe LLP
1 London Bridge
London SE1 9BG / GB
[N/P]
Former [2017/04]Finnegan Europe LLP
16 Old Bailey
London EC4M 7EG / GB
Former [2011/24]Viering, Jentschura & Partner
Kennedydamm 55/Roßstr.
40476 Düsseldorf / DE
Former [2009/14]Viering, Hans-Martin, et al
Viering, Jentschura & Partner Grillparzerstraße 14
D-81675 München / DE
Application number, filing date06780126.618.07.2006
[2009/14]
WO2006IB52461
Filing languageEN
Procedural languageEN
PublicationType: A1 Application with search report
No.:WO2008010025
Date:24.01.2008
Language:EN
[2008/04]
Type: A1 Application with search report 
No.:EP2041068
Date:01.04.2009
Language:EN
The application published by WIPO in one of the EPO official languages on 24.01.2008 takes the place of the publication of the European patent application.
[2009/14]
Type: B1 Patent specification 
No.:EP2041068
Date:25.01.2017
Language:EN
[2017/04]
Search report(s)International search report - published on:KR24.01.2008
(Supplementary) European search report - dispatched on:EP01.09.2010
ClassificationIPC:C07C327/30, A61K31/216, A61P29/00, A61P43/00
[2016/31]
CPC:
C07C233/40 (EP); A61P11/06 (EP); A61P15/00 (EP);
A61P17/00 (EP); A61P17/10 (EP); A61P19/02 (EP);
A61P25/04 (EP); A61P25/06 (EP); A61P27/02 (EP);
A61P27/06 (EP); A61P27/14 (EP); A61P27/16 (EP);
A61P29/00 (EP); A61P35/00 (EP); A61P43/00 (EP);
C07C211/63 (EP); C07C327/30 (EP) (-)
Former IPC [2010/34]C07C211/63, C07C233/40, C07C327/30, A61K31/216, A61P29/00, A61P43/00
Former IPC [2009/14]C07C211/63
Designated contracting statesAT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   NL,   PL,   PT,   RO,   SE,   SI,   SK,   TR [2017/04]
Former [2009/14]AT,  BE,  BG,  CH,  CY,  CZ,  DE,  DK,  EE,  ES,  FI,  FR,  GB,  GR,  HU,  IE,  IS,  IT,  LI,  LT,  LU,  LV,  MC,  NL,  PL,  PT,  RO,  SE,  SI,  SK,  TR 
Extension statesALNot yet paid
BANot yet paid
HRNot yet paid
MKNot yet paid
RSNot yet paid
TitleGerman:POSITIVGELADENE, WASSERLÖSLICHE PRODRUGS VON IBUPROFEN MIT EINER SEHR SCHNELLEN HAUTPENETRATIONSRATE[2009/14]
English:POSITIVELY CHARGED WATER-SOLUBLE PRODRUGS OF IBUPROFEN WITH VERY FAST SKIN PENETRATION RATE[2009/14]
French:PRO-MÉDICAMENTS D'IBUPROFÈNE HYDROSOLUBLES POSITIVEMENT CHARGÉS À TAUX DE PÉNÉTRATION CUTANÉE TRÈS RAPIDE[2009/14]
Entry into regional phase12.01.2009National basic fee paid 
12.01.2009Search fee paid 
12.01.2009Designation fee(s) paid 
12.01.2009Examination fee paid 
Examination procedure12.01.2009Examination requested  [2009/14]
28.03.2011Amendment by applicant (claims and/or description)
16.04.2013Despatch of a communication from the examining division (Time limit: M04)
16.08.2013Reply to a communication from the examining division
27.01.2015Despatch of a communication from the examining division (Time limit: M04)
22.05.2015Reply to a communication from the examining division
27.07.2016Communication of intention to grant the patent
15.11.2016Fee for grant paid
15.11.2016Fee for publishing/printing paid
15.11.2016Receipt of the translation of the claim(s)
Divisional application(s)EP17152505.8  / EP3210964
The date of the Examining Division's first communication in respect of the earliest application for which a communication has been issued is  16.04.2013
Opposition(s)26.10.2017No opposition filed within time limit [2018/01]
Fees paidRenewal fee
12.01.2009Renewal fee patent year 03
12.01.2009Renewal fee patent year 04
14.07.2010Renewal fee patent year 05
12.07.2011Renewal fee patent year 06
13.07.2012Renewal fee patent year 07
10.07.2013Renewal fee patent year 08
14.07.2014Renewal fee patent year 09
10.07.2015Renewal fee patent year 10
11.07.2016Renewal fee patent year 11
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipCY25.01.2017
EE25.01.2017
LT25.01.2017
LV25.01.2017
MC25.01.2017
SI25.01.2017
SK25.01.2017
BG25.04.2017
IS25.05.2017
LU18.07.2017
[2019/46]
Former [2019/30]EE25.01.2017
LT25.01.2017
LV25.01.2017
MC25.01.2017
SI25.01.2017
SK25.01.2017
BG25.04.2017
IS25.05.2017
LU18.07.2017
Former [2018/34]EE25.01.2017
LT25.01.2017
LV25.01.2017
SI25.01.2017
SK25.01.2017
BG25.04.2017
IS25.05.2017
LU18.07.2017
Former [2018/14]EE25.01.2017
LT25.01.2017
LV25.01.2017
SI25.01.2017
SK25.01.2017
BG25.04.2017
IS25.05.2017
Former [2017/49]EE25.01.2017
LT25.01.2017
LV25.01.2017
SK25.01.2017
BG25.04.2017
IS25.05.2017
Former [2017/41]LT25.01.2017
LV25.01.2017
BG25.04.2017
IS25.05.2017
Documents cited:Search[XY] EP0289262  (SYNTEX PHARMA INT et al.) [X] 1-5,9 * page 5, line 13 - line 37 * * page 6 - page 9 * * page 23, lines 32,34-37 * * claim - *[Y] 6-8
 [XY] EP0237495  (SIGMA TAU IND FARMACEUTI et al.) [X] 1-3,5,6 * page 1, paragraph l - page 3, paragraph 1 * * page 4 - page 5 * * pharmacological tests; page 7 - page 22 *[Y] 6,8
 [A] US2004022837  (HSU TSUNG-MIN et al.) [A] 1-9 * the whole document *
 [Y] WO02085297  (EPIGENESIS PHARMACEUTICALS INC et al.) [Y] 7 * claims 43-47,63 * * page 31, paragraphs 3-4 *
 [XY]   SHANBHAG, VRINDA R. ET AL: "Ester and amide prodrugs of ibuprofen and naproxen: synthesis, anti-inflammatory activity, and gastrointestinal toxicity", JOURNAL OF PHARMACEUTICAL SCIENCES, vol. 81, no. 2, 1992, pages 149 - 154, XP000248778, ISSN: 0022-3549 [X] 1-3 * Scheme I-III,;; compounds 4-12,14,15,18-20 * * table - * * Conclusions; page 153 *[Y] 6,8

DOI:   http://dx.doi.org/10.1002/jps.2600810210
 [XY]   VENUTI M C ET AL: "SYNTHESIS AND BIOLOGICAL EVALUATION OF OMEGA-(N,N,N-TRIALKYLAMMONIUM) ALKYL ESTERS AND THIOESTERS OF CARBOXYLIC ACID NONSTEROIDAL ANTIINFLAMMATORY AGENTS", PHARMACEUTICAL RESEARCH, vol. 6, no. 10, 1 January 1989 (1989-01-01), KLUWER ACADEMIC PUBLISHERS, NEW YORK, NY, US, pages 867 - 873, XP001098334, ISSN: 0724-8741, DOI: 10.1023/A:1015960522189 [X] 1-3 * table II; compounds 4b,4c * * page 869, column r, paragraph l - page 873, column r, paragraph l * [Y] 6,8

DOI:   http://dx.doi.org/10.1023/A:1015960522189
 [XY]   DATABASE CA [online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; 2002, SONG, NI ET AL: "Synthesis of a quaternary ammonium derivative of ibuprofen", XP002590079, retrieved from STN Database accession no. 2003:29322 [X] 1-3 * abstract *[Y] 6,8
 [XY]   SONG N ET AL: "Synthesis of a derivative quaternary ammonium-ibuprofen", JOURNAL OF OCEAN UNIVERSITY OF QINGDAO,, vol. 32, no. 6, 1 January 2002 (2002-01-01), pages 911 - 913, XP001539131, ISSN: 1001-1862 * Scheme 1; page 912 *[Y] 6,8
 [Y]   FUNT ET AL: "Oral ibuprofen and minocycline for the treatment of resistant acne vulgaris", JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, C.V. MOSBY, ST. LOUIS, MO, US LNKD- DOI:10.1016/S0190-9622(85)80375-3, vol. 13, no. 3, 1 September 1985 (1985-09-01), pages 524 - 525, XP025590312, ISSN: 0190-9622, [retrieved on 19850901] [Y] 6 * the whole document *

DOI:   http://dx.doi.org/10.1016/S0190-9622(85)80375-3
 [Y]   TJEBBES G W A ET AL: "d-Ibuprofen in ocular inflammation induced by paracentesis of the rabbit eye", PROSTAGLANDINS, vol. 40, no. 1, 1 July 1990 (1990-07-01), BUTTERWORTH, STONEHAM, MA, US, pages 29 - 33, XP023448748, ISSN: 0090-6980, [retrieved on 19900701] [Y] 8 * the whole document *

DOI:   http://dx.doi.org/10.1016/0090-6980(90)90054-Y
 [Y]   W.F. DIVEN ET AL: "Treatment of experimental acute otitis media with ibuprofen and ampicillin", INT.J.PEDIATR.OTORHINOLARYNGOL., vol. 33, 1995, pages 127 - 139, XP002590081 [Y] 8 * the whole document *
International search[X] WO03029187  (DOMPE SPA et al.) [X]
 [X] WO02068377  (DOMPE SPA et al.) [X]
 [X] WO9847502  (PAZ ARZNEIMITTELENTWICKLUNG et al.) [X]
 [X]   ALLEGRETTI M. ET AL.: "2-Arylpropionic CXC Chemokine Receptor 1 (CXCR1) Ligands as Novel Noncompetitive CXCL8 Inhibitors", JOURNAL OF MEDICINAL CHEMISTRY, vol. 48, no. 13, 27 May 2005 (2005-05-27), pages 4312 - 4331, XP008102465 [X]

DOI:   http://dx.doi.org/10.1021/JM049082I
 [X]   BIRSEN TOZKOPARAN ET AL.: "6-Benzylidenethiazolo[3,2-b]-1,24-triazole-5(6H)-ones substituted with ibuprofen: synthesis, characterization and evaluation of anti-inflammatory activity", EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, vol. 35, no. 7-8, August 2000 (2000-08-01), pages 743 - 750, XP004372928 [X]

DOI:   http://dx.doi.org/10.1016/S0223-5234(00)00157-4
 [X]   HACKING M.A.P.J. ET AL.: "Lipase catalysed acylation of hydroxylamine and hydrazine derivatives", JOURNAL OF MOLECULAR CATALYSIS B: EXZYMATIC, vol. 11, no. 4-6, 22 January 2001 (2001-01-22), pages 1147 - 1105, XP008102468 [X]

DOI:   http://dx.doi.org/10.1016/S1381-1177(00)00144-2
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.